{
    "nctId": "NCT03841266",
    "briefTitle": "Recurrence Risk Evaluation by 21-gene Detection",
    "officialTitle": "Postoperative Recurrence Risk Evaluation of Hormone Receptor Positive, Her-2 Negative Breast Cancer by Using Different 21-gene Detection Kits (REBCK)",
    "overallStatus": "COMPLETED",
    "conditions": "Relationship and Consistency Analysis",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "correlation analysis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. breast cancer in stage I-III, tumor size\\>0.5cm\n2. lymph nodes negative\n3. hormone receptor positive \uff08ER+/PR+,ER+/PR-,ER-/PR+\uff09\n4. HER2 negative\uff08IHC 0 or +\uff0c FISH negative\uff09\n5. receive endocrine therapy only\n6. enough FFPE samples within 10 years\uff083\\~6 10\u03bcm \uff09\n7. patients with integrated medical records\n\nExclusion Criteria:\n\n1. Tumor cells \\<5%\n2. Isolated RNA\\<500ng",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}